Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer

Cancer, 04/19/2012

Gemcitabine–based neoadjuvant chemotherapy confers a significant OS advantage by allowing the selection of patients who will derive greatest benefit from chemoradiation therapy (CRT). Median survival with this approach was similar to that seen with surgical resection.

Print Article Summary Cat 2 CME Report